ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 587

Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis

Carl Orr1, Aurélie Najm2, Monika Biniecka3, Francis Young1, Ursula Fearon4 and Douglas J. Veale1, 1Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, 2Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, 3St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, 4Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ACPA, Biomarkers, phenotypes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Circulating anti-citrullinated peptide antibodies (ACPA) have been proposed as an important clinical test for stratification of patients presenting with rheumatoid arthritis (RA). ACPA may be present in the serum of subjects several years before the onset of symptoms, and studies suggest that the presence of ACPA may predict more severe and erosive disease. However, studies to date investigating whether the two subgroups of RA (defined by the presence and absence of ACPA) have differing pathologies at the level of the synovial tissue, have yielded conflicting results.[1,2] The aims of our study were to examine synovial tissue immunophenotype according to ACPA status in patients with a clinical diagnosis of RA, and to determine the nature of the relationship between synovial infiltrate, response to treatment and erosions on plain film radiographs.

Methods: Consecutive patients with RA were prospectively recruited from rheumatology clinics and underwent clinical, serological and radiological assessment before and after treatment with non-biologic DMARD (nbDMARD) or TNF inhibitors (TNFi). Synovial tissue was obtained by arthroscopy from involved knee joints and immunohistologically stained for cell specific markers of B-cells (CD19), T-cells (CD3, CD4 and CD8), macrophages (CD68) and the blood vessel marker FVIII. Sections were scored using a validated semi-quantitative scoring method and analysis of synovial immuno-phenotype by ACPA status and EULAR response criteria to treatment was performed.

Results: 123 subjects (78 ACPA+) were included in the study. The synovium from ACPA+ RA was characterised by significantly higher CD19+ B-cells (p<0.05), CD3+ T cells (p<0.05) and CD8+ T cells (p<0.05), compared with ACPA- RA. CD19+ B-cells were also significantly higher in the synovium of ACPA+ patients naïve to treatment (p=0.04) (fig. 1). In addition, both CD19+ B-cell and CD4+ T-cell infiltrates were higher in patients who had evidence of erosive disease at follow-up (p=0.0163; p=0.0024, respectively).  RA patients achieving a moderate-good EULAR response to nbDMARD or TNFi also had significantly higher infiltrates of CD3+ cells (P<0.05).  Finally, CD68+ and CD8+ cells were significantly higher in TNFi responders vs non responders (p<0.05)

Conclusion: ACPA+ RA patients demonstrate significantly higher synovial B and T cell infiltrates and higher B cells were identified in treatment-naïve patients and associated with the erosions. 1            van Oosterhout M, et al. Arthritis Rheum 2008;58:53–60. 2            Gomez-Puerta JA, et al.. Arthritis Res Ther 2013;15:R182. Figure 1:


Disclosure: C. Orr, None; A. Najm, None; M. Biniecka, None; F. Young, None; U. Fearon, None; D. J. Veale, None.

To cite this abstract in AMA style:

Orr C, Najm A, Biniecka M, Young F, Fearon U, Veale DJ. Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/synovial-immunophenotype-and-anti-citrullinated-protein-antibodies-in-rheumatoid-arthritis-patients-relationship-to-treatment-response-and-radiological-prognosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-immunophenotype-and-anti-citrullinated-protein-antibodies-in-rheumatoid-arthritis-patients-relationship-to-treatment-response-and-radiological-prognosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology